Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.

INTRODUCTION: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed against IL-5. AREAS COVERED: This review presents the available data on benralizumab, including pharmacodynamics, pharmacokinetics, preclinical data and relevant clinical studies. EXPERT OPINION: Our review indicates that although further investigation is necessary to demonstrate clinical benefit, benralizumab remains a promising treatment modality.

Pubmed ID: 22136436 RIS Download

Mesh terms: Antibodies, Monoclonal | Antibodies, Monoclonal, Humanized | Antibodies, Neutralizing | Asthma | Clinical Trials as Topic | Eosinophils | Humans | Immunotherapy | Inflammation | Interleukin-5 | Interleukin-5 Receptor alpha Subunit | Models, Biological | Models, Genetic | Phenotype | Time Factors | Treatment Outcome